文献类型：期刊文献

英文题名：Establishment and characterization of CHC-X1: the third human combined hepatocellular-cholangiocarcinoma cell line

作者：Tang, Huan[1];Chai, Changpeng[2,3];Miao, Xin[4];Su, Yuanhui[1];Yu, Cheng[1,5];Yi, Jianfeng[3,6];Wang, Zhengfeng[2,3];Zhang, Hui[1,7];Zhao, Zhenjie[2,3];Wang, Linpei[8,10];Zhou, Wence[1,7,10];Xu, Hao[2,3,9,10]

第一作者：Tang, Huan

通信作者：Zhou, WC[1];Xu, H[2];Xu, H[3];Zhou, WC[4];Wang, LP[5];Xu, H[6];Wang, LP[7];Zhou, WC[7];Xu, H[7]

机构：[1]Lanzhou Univ, Clin Med Sch 2, Lanzhou 730000, Peoples R China;[2]First Hosp Lanzhou Univ, Dept Gen Surg 4, Lanzhou 730000, Peoples R China;[3]Lanzhou Univ, First Clin Med Sch, Lanzhou 730000, Peoples R China;[4]Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Dept Nephrol, Hangzhou 310006, Peoples R China;[5]Lanzhou Univ Second Hosp, Dept Anesthesiol, Lanzhou 730000, Peoples R China;[6]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou 730000, Peoples R China;[7]Lanzhou Univ Second Hosp, Dept Gen Surg, Lanzhou 730000, Peoples R China;[8]Fujian Med Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 2, Quanzhou 362000, Peoples R China;[9]Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Dept Hepatobiliary Surg, Hangzhou 310006, Zhejiang, Peoples R China;[10]54 Youdian Rd, Hangzhou, Zhejiang, Peoples R China

第一机构：Lanzhou Univ, Clin Med Sch 2, Lanzhou 730000, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Clin Med Sch 2, Lanzhou 730000, Peoples R China;[2]corresponding author), First Hosp Lanzhou Univ, Dept Gen Surg 4, Lanzhou 730000, Peoples R China;[3]corresponding author), Lanzhou Univ, First Clin Med Sch, Lanzhou 730000, Peoples R China;[4]corresponding author), Lanzhou Univ Second Hosp, Dept Gen Surg, Lanzhou 730000, Peoples R China;[5]corresponding author), Fujian Med Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 2, Quanzhou 362000, Peoples R China;[6]corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Dept Hepatobiliary Surg, Hangzhou 310006, Zhejiang, Peoples R China;[7]corresponding author), 54 Youdian Rd, Hangzhou, Zhejiang, Peoples R China.

年份：2025

卷号：25

期号：1

外文期刊名：BMC CANCER

收录：;Scopus(收录号：2-s2.0-105000195700);WOS:【SCI-EXPANDED(收录号:WOS:001445485600001)】；

基金：We would like to thank Bullet Edits (http://www.bulletedits.cn) for English language editing of the manuscript.

语种：英文

外文关键词：Combined hepatocellular-cholangiocarcinoma; Cell lines; Transplanted tumor; Drug sensitivity; Drug resistance

摘要：Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) represents an uncommon variant of primary liver cancer. In recent years, its incidence rate has increased. Thus, it is essential to perform comprehensive investigations into cHCC-CCA to develop suitable treatment strategies. So far, only two cell lines (CLs) of this cancer type have been reported. More cHCC-CCA CLs need to be established for research purposes. In this investigation, we developed a stable cHCC-CCA CL, named CHC-X1. STR analysis confirmed that CHC-X1 is a new human cHCC-CCA CL. CHC-X1 is a complex karyotype. Its population doubling time is 50.72 h. Under suspended conditions, CHC-X1 can form tumor spheres and organoids in Matrigel. These cells exhibit sensitivity to paclitaxel while demonstrating resistance against oxaliplatin, gemcitabine, and 5-FU. After inoculation into NXG mice, CHC-X1 can quickly form subcutaneous transplant tumors, exhibiting a tumor establishment rate of 67%. Immunohistochemical staining showed that CHC-X1 is a tumor CL with both liver cell differentiation and bile duct cell differentiation characteristics. It may function as a useful model for identifying the origins of cHCC-CCA and the advancement of potential treatments.